Top Qs
Timeline
Chat
Perspective
Zilucoplan
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Zilucoplan, sold under the brand name Zilbrysq, is a medication used for the treatment of generalized myasthenia gravis.[6][9][10] It is a complement inhibitor that is injected subcutaneously (under the skin).[6]
Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b.[11]
Zilucoplan was approved for medical use in the United States in October 2023,[6][12] in the European Union in December 2023,[7] and in Australia in July 2024.[1]
Remove ads
Medical uses
Zilucoplan is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.[6]
Society and culture
Legal status
In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zilbrysq, intended for the treatment of myasthenia gravis.[13] The applicant for this medicinal product is UCB Pharma S.A.[13] Zilucoplan was approved for medical use in the Europea Union in December 2023.[7]
Zilucoplan was granted orphan drug designation by the US Food and Drug Administration (FDA) in August 2019,[14] and by the EMA in July 2022.[15]
Brand names
Zilucoplan is the international nonproprietary name.[16]
Zilucoplan is sold under the brand name Zilbrysq.[7]
Remove ads
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads